Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018
WILMINGTON, Del.--(BUSINESS WIRE)--Sep 6, 2018--Incyte Corporation (Nasdaq:INCY) today announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement. Dave plans to remain at Incyte until the end of this year and will provide support during the transitional period.
“Since joining Incyte in 2014, Dave has been an invaluable part of the leadership team. I would like to take this opportunity to thank him for all of his contributions—Dave has helped place Incyte on a firm financial footing, and his expertise has ensured that Incyte has all the necessary systems in place to facilitate our international expansion as we pursue our mission of bringing innovative therapies to patients in need around the world,” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “As we wish Dave all the best for a long and healthy retirement, we look forward to welcoming his successor who will help us navigate our exciting future as we seek to build a fast-growing, profitable, global biopharmaceutical company.”
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding Mr. Gryska’s plans to remain with Incyte through the end of 2018, Incyte’s mission to bring innovative treatments to patients and Incyte’s efforts to become a fast-growing, profitable, global biopharmaceutical company, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005919/en/
CONTACT: Incyte Corporation
Catalina Loveman, +1 302-498-6171
Michael Booth, DPhil, +1 302-498-5914
KEYWORD: UNITED STATES NORTH AMERICA DELAWARE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Incyte Corporation
Copyright Business Wire 2018.
PUB: 09/06/2018 04:30 PM/DISC: 09/06/2018 04:30 PM